[PDF][PDF] Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical …
MG Kris, LE Gaspar, JE Chaft, EB Kennedy… - J Clin …, 2017 - cancercareontario.ca
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely
Resected Non–Small-Cell Lung Cancers: Page 1 JOURNAL OF CLINICAL ONCOLOGY …
Resected Non–Small-Cell Lung Cancers: Page 1 JOURNAL OF CLINICAL ONCOLOGY …
[HTML][HTML] Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the
development of anticancer immunotherapy agents has thrived. The success of many …
development of anticancer immunotherapy agents has thrived. The success of many …
A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors
BP Venkatesulu, S Mallick, SH Lin… - Critical reviews in oncology …, 2018 - Elsevier
Lymphopenia is a common accompaniment of multimodal cancer therapy. As the most
radiosensitive cells of the hematopoietic system, lymphocytes residing within or circulating …
radiosensitive cells of the hematopoietic system, lymphocytes residing within or circulating …
Integrating genomic features for non-invasive early lung cancer detection
Radiologic screening of high-risk adults reduces lung-cancer-related mortality,; however, a
small minority of eligible individuals undergo such screening in the United States,. The …
small minority of eligible individuals undergo such screening in the United States,. The …
The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression
Ferroptosis, a form of regulated cell death caused by lipid peroxidation, was recently
identified as a natural tumor suppression mechanism. Here, we show that ionizing radiation …
identified as a natural tumor suppression mechanism. Here, we show that ionizing radiation …
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
WSME Theelen, D Chen, V Verma… - The Lancet …, 2021 - thelancet.com
Background Radiotherapy might augment systemic antitumoral responses to
immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with …
immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with …
[HTML][HTML] Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects
YL Xu, RK Reinscheid, S Huitron-Resendiz, SD Clark… - Neuron, 2004 - cell.com
Arousal and anxiety are behavioral responses that involve complex neurocircuitries and
multiple neurochemical components. Here, we report that a neuropeptide, neuropeptide S …
multiple neurochemical components. Here, we report that a neuropeptide, neuropeptide S …
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified …
JY Chang, RJ Mehran, L Feng, V Verma, Z Liao… - The Lancet …, 2021 - thelancet.com
Background A previous pooled analysis of the STARS and ROSEL trials showed higher
survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early …
survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early …
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer
PURPOSE: Although 3-dimensional conformal radiotherapy (3D-CRT) is the worldwide
standard for the treatment of esophageal cancer, intensity modulated radiotherapy (IMRT) …
standard for the treatment of esophageal cancer, intensity modulated radiotherapy (IMRT) …
[HTML][HTML] Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
Background In this phase I/II trial, we evaluated the safety and effectiveness of
pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from …
pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from …